Subsense Inc.

Today, our CEO Tetiana Aleksandrova took the stage at WOMEN IN AI · The Debate at the Googleplex, and left inspired. It was a women-led debate on the questions that actually matter right now: How do we lead progress responsibly in the AI era? How is AI reshaping the way we build and manage companies and products? What perspective do women bring to AI that would otherwise be missing? And what will the AGI era look like, and when will it arrive? Tetiana's message was direct: be brave, be active, and engage early with your audience and investors. Being a female founder isn't a footnote to the work. It shapes it. Women bring a perspective that leads to stronger, safer execution and to products the world can actually trust. That last point sits at the core of what we're building at Subsense. When technology connects directly to the human brain, safety and responsibility aren't features you add later. They are the whole job. Rooms like this one, and the honesty and cooperation in them, are how the field gets it right. Thank you to ISOUL and Jane Milovanova for creating a space where women don't just attend the conversation about AI. They lead it. #WomenInAI #ArtificialIntelligence #Neurotechnology #WomenInTech #Leadership #SiliconValley #ISOUL #BCI

This Friday our CEO, Tetiana Aleksandrova, joins WOMEN IN AI · The Debate at the Googleplex, where women building, funding, and questioning AI argue the questions the industry usually dodges: Who gets to build the models that shape everyone's reality? What does responsible AI leadership actually look like, and who defines it? Those questions hit differently when the technology connects directly to the human brain. That's the work Tetiana leads at Subsense, and the perspective she's bringing to the room: as AI moves closer to our biology, the debate over who shapes it stops being abstract. DM her if want to join! #WomenInAI #ArtificialIntelligence #Neurotechnology #WomenInTech #Leadership #SiliconValley #ISOUL #BCI

The future of BCIs depends on more than scientific breakthroughs. It requires thoughtful conversations about how safety, ethics, and responsible innovation will shape the technologies that ultimately reach patients. Our CEO, Tetiana Aleksandrova, shares her perspective in her latest Forbes Technology Council article on why building trust begins with designing BCIs for safety from day one. https://lnkd.in/gKUJH9jE 

The field of BCI is expanding, but the biggest advances ahead won’t come from making today's technology incrementally better. They will come from rethinking the problem entirely. BCIs can transform brain health, but to do so, the technology needs to be practical enough for the people they're meant to serve. Our Head of R&D, Scott Meek, Ph.D., spoke with BioWorld News about why reducing barriers to adoption is just as important as advancing the science, and why novel approaches like the one we’re developing at Subsense could help expand access to BCI technology. As the article notes, the next generation of BCI companies is building on the lessons of the pioneers, exploring new technologies, addressing long-standing challenges and expanding the possibilities for patients. We're excited to be part of that evolution. Read the fully story here: https://lnkd.in/gZKX8XyA

Faster and Safer Aren’t a Trade-Off China just issued a reimbursement code for the world’s first commercial brain implant — within days of approving it. The US still treats coverage as a separate fight that can take years. That gap, not the technology, is the real race. Here’s the backdrop. Two of China’s leading BCI companies, Neuracle and BrainCo, are heading for the public markets — one on Shanghai’s STAR Market, the other in Hong Kong. First-half funding has already passed RMB 4 billion (~$556M), above the full 2025 total and up roughly 230% from the same period last year. A lot of people frame this as a technology race. That misses the more useful story. Western programs still lead on signal quality and depth of clinical evidence. China moved this fast because its policy was built for the pace — standards and pricing set before products existed, and approval tied directly to reimbursement. That’s a model worth studying. The US has the opposite problem. FDA approval is only the starting line. Coverage is a separate process: Medicare and private insurers each decide on their own, which for a novel device can take years — with no guarantee at the end. Of the novel medical technologies the US authorized between 2016 and 2019, fewer than half ever secured Medicare coverage. The field has a name for this gap: the reimbursement valley of death. And the cost is measured in patients. People with Parkinson’s, drug-resistant epilepsy, and paralysis are waiting years longer than the science requires. So the opportunity is clear. Build coverage alongside regulatory review, not years after it. Make timelines predictable enough to plan around. Set standards early, and set them high. Moves like the proposed RAPID pathway point the right way and deserve to become the norm. Speed and trust have to advance together. For a field that reads and writes to the human brain, neural-data rights, informed consent, and long-term safety aren’t features you add later — they’re the foundation you build on. Should coverage review run in parallel with FDA approval — or does that risk lowering the bar? Curious where people land. #BCI #Neurotech #HealthPolicy #PatientAccess #ResponsibleInnovation

We’re excited to welcome Parminder Mankoo as Head of AI and Amy Peck as Head of Partnerships at Subsense. We’re building the next phase of Subsense around smarter AI systems, stronger industry collaborations, and technology that can reach more patients. Parminder and Amy will be a big part of helping us get there. Parminder brings more than 15 years of experience spanning AI and computational sciences across translational medicine in pharma and biotech R&D. Most recently serving as Chief Technology Officer at Synamics Therapeutics and previously Vice President of Computational Sciences at Liberate Bio, Parminder has led the development of AI/ML-powered platforms for drug discovery, including generative AI approaches for molecular and predictive modeling, and large-scale biological and chemical data analysis. Amy was the Founder and CEO of EndeavorXR and is widely recognized as a leading strategist for advanced technologies, from digital twins and AI to healthcare services. Named among the Top 50 Most Powerful Women in Tech and Top 100 Women of the Future, she has worked closely with Fortune 500 companies and emerging startups, helping organizations build strategic partnerships to accelerate the adoption of next-generation platforms.

AI is becoming an integral part of our lives. The interface between humans and computers will matter more than ever. Our CEO Tetiana Aleksandrova explores an important question: if brain-computer interfaces become part of the future AI ecosystem, what kind of interfaces are we actually creating for greater accessibility? The article published in The AI Journal also features insights from John-Clark Levin and the growing need for BCI technologies that do not require surgery, especially important as computing systems advance. The future of BCI will depend not only on technicality, but also on scalability and safety. https://lnkd.in/gXRTsFt7

New from our CEO, Tetiana Aleksandrova in Forbes: “BCI Can Reach Millions. Neurotech Decided It Shouldn’t.” The future of #BCI will not be determined only by signal quality or hardware performance. It will also depend on how we prioritize accessibility, scalability and real-world adoption from the beginning. Reaching more patients requires challenging assumptions that have influenced BCI for decades. That includes: - Bringing in perspectives outside traditional neurotech - Developing systems built for broader deployment - Generating data that supports scalable, non-surgical approaches A thoughtful perspective from Tetiana on where BCI goes next and how Subsense plans to get there. https://lnkd.in/gykTvXyR

We’re excited and privileged to welcome visionary leader David Eagleman as he joins Subsense’s Scientific Advisory Board. Dr. Eagleman brings deep expertise across neuroscience innovation, brain remodeling, and the evolving relationship between humans and next-generation technology. Dr. Eagleman is a renowned neuroscientist from Stanford University, an internationally bestselling author, and co-founder of Neosensory, Inc. and BrainCheck. He is known for his work in sensory substitution, brain plasticity, time perception, synesthesia, and neurolaw, and for bringing neuroscience to global audiences through The Brain with David Eagleman on PBS and The Creative Brain on Netflix. He has authored 120+ scientific publications and numerous acclaimed books, including Livewired: The Inside Story of the Ever-Changing Brain and New York Times bestseller Incognito: The Secret Lives of the Brain. A Guggenheim Fellow and TED speaker, he has been recognized with the Claude Shannon Luminary Award and the McGovern Award for Excellence in Biomedical Communication. Dr. Eagleman will provide invaluable insights during Subsense’s pivotal stage of growth. We’re grateful to have his support as we advance our nanoparticle, non-surgical brain-computer interface platform.

Ready to build what’s next in neurotech? We’re creating the future of non-surgical brain-computer interfaces at Subsense and looking for exceptional people to make it real. We need ambitious builders, operators and innovators ready to tackle hard problems. Open Roles: Chief Financial Officer Head of Product Head of Partnerships Head of AI Marketing Communications Lead Neurotech Engineer DevOps Engineer Apply for your next career: https://lnkd.in/dX_F_Haq